Portal de Periódicos da CAPES

Lack of evidence of isoniazid efficacy for the treatment of MDR/XDR-TB in the presence of the katG 315T mutation

2017; European Respiratory Society; Volume: 50; Issue: 4 Linguagem: Inglês

10.1183/13993003.01752-2017

1399-3003

Dumitru Chesov, Nelly Ciobanu, Christoph Lange, Thomas Schön, Jan Heyckendorf, Valeriu Crudu,

Diagnosis and treatment of tuberculosis

We are grateful for the response by E. Heldal to our correspondence. Similar to other reports [1] from the World Health Organization (WHO) Euro-Region we found that a high proportion (88%) of Mycobacterium tuberculosis strains from patients with multidrug-resistant (MDR)/extensively drug-resistant (XDR) tuberculosis (TB) in the Republic of Moldova had a katG 315T mutation, which is strongly suggestive that high-dose isoniazid should not be part of a standardised treatment regimen for patients with MDR/XDR-TB in this country. Further studies are needed to address the possible benefits of high-dose isoniazid therapy adequately